Febuxostat Fahrenheit Drug Interactions

Mercaptopurine/azathioprine: On the basis of the mechanism of action of Febuxostat on XO inhibition concomitant use is not recommended. Inhibition of XO by Febuxostat may cause increased plasma concentration of these drugs leading to toxicity. Drug interaction studies of Febuxostat with drugs that are metabolized by XO have not been performed.
Drug interaction studies of Febuxostat with cytotoxic chemotherapy have not been conducted. No data is available regarding the safety of Febuxostat during cytotoxic therapy.
CYP2C8 substrates: Co-administration of Febuxostat with rosiglitazone or other CYP2C8 substrates is not expected to require any dose adjustment for those compounds.
Theophylline: No special caution is advised when febuxostat 80 mg and theophylline are given concomitantly. No data is available for febuxostat 120 mg.
Naproxen and other inhibitors of glucuronidation: Febuxostat metabolism depends on Uridine Glucuronosyl Transferase (UGT) enzymes. Medicinal products that inhibit glucuronidation such as NSAIDs and probenecid, could in theory affect the elimination of febuxostat.
Febuxostat can be co-administered with naproxen with no dose adjustment of febuxostat or naproxen being necessary.
Inducers of glucuronidation: Potent inducers of UGT enzymes might possibly lead to increased metabolism and decreased efficacy of Febuxostat. Monitoring of serum uric acid is therefore recommended 1-2 weeks after start of treatment with a potent inducer of glucuronidation. Conversely, cessation of treatment of an inducer might lead to increased plasma levels of febuxostat.
Colchicine/indomethacin/hydrochlorothiazide/warfarin: Febuxostat can be co-administered with colchicine or indomethacin with no dose adjustment of febuxostat or the co-administered active substance being necessary.
No dose adjustment is necessary for febuxostat when administered with hydrochlorothiazide.
No dose adjustment is necessary for warfarin when administered with febuxostat. Administration of febuxostat (80 mg or 120 mg once daily) with warfarin had no effect on the pharmacokinetics of warfarin. INR and Factor VII activity were also not affected by the co-administration of Febuxostat.
Desipramine/CYP2D6 substrates: Co-administration of Febuxostat with other CYP2D6 substrates in not expected to require any dose adjustment for those compounds.
Antacids: Febuxostat may be taken without regard to antacid use.